IGF2BP3 K76la upregulates PCK2 expression in lenvatinib-resistant hepatocellular carcinoma cells, triggering serine metabolism reprogramming and conferring drug resistance (Lu et al., 2024). This evidence concerns the gene PCK2 and hepatocellular carcinoma.